JP2020526477A - 安定型ニコチンアミドリボシド組成物及びその調製方法 - Google Patents
安定型ニコチンアミドリボシド組成物及びその調製方法 Download PDFInfo
- Publication number
- JP2020526477A JP2020526477A JP2019563756A JP2019563756A JP2020526477A JP 2020526477 A JP2020526477 A JP 2020526477A JP 2019563756 A JP2019563756 A JP 2019563756A JP 2019563756 A JP2019563756 A JP 2019563756A JP 2020526477 A JP2020526477 A JP 2020526477A
- Authority
- JP
- Japan
- Prior art keywords
- nicotinamide riboside
- composition
- stable
- rebaudioside
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title claims abstract description 99
- 235000020956 nicotinamide riboside Nutrition 0.000 title claims abstract description 88
- 239000011618 nicotinamide riboside Substances 0.000 title claims abstract description 87
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title description 9
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims abstract description 46
- 229920002581 Glucomannan Polymers 0.000 claims abstract description 46
- 229920002752 Konjac Polymers 0.000 claims abstract description 46
- 229940046240 glucomannan Drugs 0.000 claims abstract description 46
- 235000010485 konjac Nutrition 0.000 claims abstract description 46
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims abstract description 37
- 239000000252 konjac Substances 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- GIPHUOWOTCAJSR-UHFFFAOYSA-N Rebaudioside A. Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O GIPHUOWOTCAJSR-UHFFFAOYSA-N 0.000 claims abstract description 7
- 241001312219 Amorphophallus konjac Species 0.000 claims abstract 7
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 36
- 239000001512 FEMA 4601 Substances 0.000 claims description 35
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 claims description 35
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 claims description 35
- 235000019203 rebaudioside A Nutrition 0.000 claims description 35
- 239000000843 powder Substances 0.000 claims description 22
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000011570 nicotinamide Substances 0.000 claims description 8
- 229960003966 nicotinamide Drugs 0.000 claims description 8
- 235000005152 nicotinamide Nutrition 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 238000006911 enzymatic reaction Methods 0.000 claims description 5
- YABIFCKURFRPPO-IVOJBTPCSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;chloride Chemical group [Cl-].NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 YABIFCKURFRPPO-IVOJBTPCSA-N 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 150000008223 ribosides Chemical class 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 30
- -1 nicotinamide nucleoside Chemical class 0.000 description 11
- 239000007787 solid Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229930188195 rebaudioside Natural products 0.000 description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Chemical compound CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 238000000859 sublimation Methods 0.000 description 3
- 230000008022 sublimation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000544066 Stevia Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical group 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cosmetics (AREA)
- Jellies, Jams, And Syrups (AREA)
Abstract
Description
従来技術に比べて、本発明によるニコチンアミドリボシド組成物は、性質が安定的であり、保存及び輸送が容易であり、加速試験を通じて測定したところ、該組成物は、6ヵ月の試験期間に亘って重要な観察指標のいずれにも大きな変化がなく、且つ調製プロセスがシンプルであり、コストが低く、産業的な量産に向いている。
原料:ニコチンアミドリボシドのアモルファス粉末50g、コンニャクグルコマンナンのアモルファス粉末100g、レバウディオサイドAのアモルファス粉末100g
調製:原料として上記ニコチンアミドリボシドとコンニャクグルコマンナン又はレバウディオサイドAを均一に混合し、本発明の安定型ニコチンアミドリボシド組成物を得た。
原料:ニコチンアミドリボシドクロリドのアモルファス粉末60g、コンニャクグルコマンナンのアモルファス粉末60g、レバウディオサイドAのアモルファス粉末60g
調製:原料として上記ニコチンアミドリボシドクロリドとコンニャクグルコマンナン又はレバウディオサイドAを均一に混合し、本発明の安定型ニコチンアミドリボシド組成物を得た。
原料:ニコチンアミドリボシドのアモルファス粉末50g、コンニャクグルコマンナンのアモルファス粉末90g、レバウディオサイドAのアモルファス粉末90g
調製:上記ニコチンアミドリボシドを水1Lに溶解して、塩酸を加えてpH値を3−4に調整し、次に、上記コンニャクグルコマンナン又はレバウディオサイドAを加え、撹拌して十分に溶解させて均一に混合し、最後に、凍結乾燥装置において乾燥における昇華温度を25℃以下に制御しながら乾燥させ、本発明の安定型ニコチンアミドリボシド組成物を得た。
原料:酵素触媒法(ニコチンアミドモノヌクレオチド(NMN)を基質、酸性ホスファターゼ(EC 3.1.3.2)を触媒とした)によりニコチンアミドリボシドを調製して得た酵素反応液、適量のコンニャクグルコマンナンのアモルファス粉末、適量のレバウディオサイドAのアモルファス粉末
調製:上記酵素反応液を精製することで、不純物をニコチンアミドリボシドの純度が90%以上となるまで除去し、次に、ニコチンアミドリボシドの濃度が60g/Lとなるまで濃縮させ、さらに塩酸を加えてpH値を3−4に調整し、次に、最終濃度が90g/Lとなるまでコンニャクグルコマンナン又はレバウディオサイドAを加え、撹拌して十分に溶解させて均一に混合し、最後に、凍結乾燥装置において乾燥における昇華温度を25℃以下に制御しながら乾燥させ、本発明の安定型ニコチンアミドリボシド組成物を得た。
安定性の加速試験
2015版『中国薬局方』に記載の医薬品安定性試験の指導原則における規定にしたがって、試験対象(ニコチンアミドリボシド及び本発明の実施例1〜実施例4で調製されたニコチンアミドリボシド組成物)について安定性加速試験を行い、試験方法は、以下のとおりである。試験対象ごとに3つサンプリングし、温度25℃±2℃、相対湿度60%±10%の環境に放置し、試験期間において0ヵ月目、1ヵ月目、2ヵ月目、3ヵ月目及び6ヵ月目の末期にそれぞれ1回サンプリングし、HPLCによってニコチンアミドリボシドの純度を検出し、3つの平均値を算出した。試験結果を表1に示し、表中、第1列に記載の1、2、3及び4は、それぞれ実施例1、実施例2、実施例3及び実施例4を表し、NRは、ニコチンアミドリボシドを表し、KGMは、コンニャクグルコマンナンを表し、RAは、レバウディオサイドAを表す。
Claims (10)
- 安定型ニコチンアミドリボシド組成物であって、
ニコチンアミドリボシド及び/又はその塩、及びコンニャクグルコマンナン又はレバウディオサイドAを含む、ことを特徴とする安定型ニコチンアミドリボシド組成物。 - 前記ニコチンアミドリボシド塩は、ニコチンアミドリボシドクロリドである、ことを特徴とする請求項1に記載の安定型ニコチンアミドリボシド組成物。
- 前記組成物において、重量部基準で、ニコチンアミドリボシド及び/又はその塩:コンニャクグルコマンナン又はレバウディオサイドA=1:1−2である、ことを特徴とする請求項1に記載の安定型ニコチンアミドリボシド組成物。
- 前記組成物は、アモルファス粉末である、ことを特徴とする請求項1に記載の安定型ニコチンアミドリボシド組成物。
- 前記組成物における前記ニコチンアミドリボシド及び/又はその塩の含有量が10重量%以上である、ことを特徴とする請求項1に記載の安定型ニコチンアミドリボシド組成物。
- 安定型ニコチンアミドリボシド組成物の調製方法であって、
ニコチンアミドリボシド及び/又はその塩、及びコンニャクグルコマンナン又はレバウディオサイドAをそれぞれ秤取し、均一に混合することを含む、ことを特徴とする安定型ニコチンアミドリボシド組成物の調製方法。 - 安定型ニコチンアミドリボシド組成物の調製方法であって、
ニコチンアミドリボシドの水溶液に塩酸を加えてpH値を3−4に調整し、次に、コンニャクグルコマンナン又はレバウディオサイドAを加えて十分に溶解し、均一に混合して凍結乾燥させることを含む、ことを特徴とする安定型ニコチンアミドリボシド組成物の調製方法。 - 前記ニコチンアミドリボシドの水溶液は、酵素触媒法によりニコチンアミドリボシドを調製して得た酵素反応液から不純物を除去した溶液である、ことを特徴とする請求項7に記載の安定型ニコチンアミドリボシド組成物の調製方法。
- ニコチンアミドリボシドの安定性の向上方法であって、
ニコチンアミドリボシド及び/又はその塩にコンニャクグルコマンナン又はレバウディオサイドAを加えて、ニコチンアミドリボシド及び/又はその塩とコンニャクグルコマンナン又はレバウディオサイドAを、均一に混合した状態で共存させる、ことを特徴とするニコチンアミドリボシドの安定性の向上方法。 - 医薬品、サプリメント又はスキンケア製品であって、
請求項1〜5のいずれか1項に記載の安定型ニコチンアミドリボシド組成物を含む、ことを特徴とする医薬品、サプリメント又はスキンケア製品。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/101175 WO2019210607A1 (zh) | 2018-08-17 | 2018-08-17 | 一种稳定型烟酰胺核糖组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020526477A true JP2020526477A (ja) | 2020-08-31 |
JP6887025B2 JP6887025B2 (ja) | 2021-06-16 |
Family
ID=68386261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019563756A Active JP6887025B2 (ja) | 2018-08-17 | 2018-08-17 | 安定型ニコチンアミドリボシド組成物及びその調製方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US11052100B2 (ja) |
JP (1) | JP6887025B2 (ja) |
CN (1) | CN110913864B (ja) |
WO (1) | WO2019210607A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111454311B (zh) * | 2020-04-03 | 2021-10-19 | 深圳市迪克曼科技开发有限公司 | 烟酰胺核糖的有机酸盐及其组合物与制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130165398A1 (en) * | 2010-03-29 | 2013-06-27 | Paul Hochegger | Concentration-enhancing drink |
WO2015099842A1 (en) * | 2013-12-23 | 2015-07-02 | Abbott Laboratories | Hot beverage fortifier |
CN106955290A (zh) * | 2017-03-24 | 2017-07-18 | 南京顺昌医药科技有限公司 | 一种治疗退化性疾病的组合物及其用途 |
WO2018027070A1 (en) * | 2016-08-04 | 2018-02-08 | Seattle Gummy Company | Compositions for athletic performance and methods of making and using thereof |
WO2018027081A1 (en) * | 2016-08-04 | 2018-02-08 | Seattle Gummy Company | Health management compositions and methods of making and using thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB931438A (ja) * | 1960-11-01 | |||
JP5663576B2 (ja) * | 2010-07-06 | 2015-02-04 | 上西 秀則 | 神経突起伸長剤 |
JP5860542B2 (ja) * | 2011-11-23 | 2016-02-16 | コリア フード リサーチ インスティテュート | 甘味増強剤 |
CN102793265B (zh) * | 2012-09-13 | 2015-01-07 | 中国烟草总公司郑州烟草研究院 | 一种天然烟草保润增香剂的制备方法及其在卷烟中的应用 |
CA2915103A1 (en) * | 2013-07-31 | 2015-02-05 | Dsm Ip Assets B.V. | Stable sweetener compositions |
KR20210107895A (ko) * | 2013-10-30 | 2021-09-01 | 크로마덱스 아이엔씨. | 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물 |
HUE045992T2 (hu) * | 2014-10-03 | 2020-01-28 | Conagen Inc | Kalóriamentes édesítõszerek és szintézismódszereik |
US20160374908A1 (en) * | 2015-06-29 | 2016-12-29 | The Procter & Gamble Company | Skin care composition and methods of using the same |
WO2018089830A1 (en) * | 2016-11-11 | 2018-05-17 | The Queen's University Of Belfast | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
-
2018
- 2018-08-17 WO PCT/CN2018/101175 patent/WO2019210607A1/zh active Application Filing
- 2018-08-17 CN CN201880037969.2A patent/CN110913864B/zh active Active
- 2018-08-17 JP JP2019563756A patent/JP6887025B2/ja active Active
- 2018-08-17 US US16/609,168 patent/US11052100B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130165398A1 (en) * | 2010-03-29 | 2013-06-27 | Paul Hochegger | Concentration-enhancing drink |
WO2015099842A1 (en) * | 2013-12-23 | 2015-07-02 | Abbott Laboratories | Hot beverage fortifier |
WO2018027070A1 (en) * | 2016-08-04 | 2018-02-08 | Seattle Gummy Company | Compositions for athletic performance and methods of making and using thereof |
WO2018027081A1 (en) * | 2016-08-04 | 2018-02-08 | Seattle Gummy Company | Health management compositions and methods of making and using thereof |
CN106955290A (zh) * | 2017-03-24 | 2017-07-18 | 南京顺昌医药科技有限公司 | 一种治疗退化性疾病的组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
US20200323891A1 (en) | 2020-10-15 |
JP6887025B2 (ja) | 2021-06-16 |
WO2019210607A1 (zh) | 2019-11-07 |
CN110913864B (zh) | 2022-12-13 |
US11052100B2 (en) | 2021-07-06 |
CN110913864A (zh) | 2020-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI554274B (zh) | 黏土組成物 | |
JPS58164683A (ja) | 安定化された固体組成物 | |
PT86131B (pt) | Processo para a preparacao de uma composicao edulcorante | |
CN101502656B (zh) | 一种可溶且稳定的大环内酯类药物苦味消除组合物 | |
JP2002528063A (ja) | 甘味料 | |
JP6887025B2 (ja) | 安定型ニコチンアミドリボシド組成物及びその調製方法 | |
CN102617643B (zh) | 一种核黄素磷酸钠化合物 | |
JP2006052169A (ja) | ゾル状又はゲル状の服薬補助食品 | |
JPS62186773A (ja) | 飲料製造用非吸湿性水溶性粉末状組成物およびその製造方法 | |
JP5071112B2 (ja) | S−アデノシル−l−メチオニンの安定化法及び安定化された組成物 | |
JP2005325080A (ja) | パントテン酸カルシウム及びビタミン類を含む組成物 | |
WO1996038058A1 (fr) | Composition contenant du calcium facilement absorbable et son procede de fabrication | |
JP2006254906A (ja) | 「なき」の抑制されたマルチトール含有ハードキャンディとその製造方法 | |
JP4208759B2 (ja) | 安定なアジスロマイシン非二水和物経口懸濁剤 | |
CN110721195A (zh) | 一种羧甲基壳聚糖多孔骨架型硫酸软骨素a纳米硒控释片及其制备方法 | |
JP2008308430A (ja) | ヒアルロン酸生成増強剤 | |
CA3094384A1 (en) | Highly stable formulations of thyroid hormone in soft capsules | |
JP4178361B2 (ja) | キトサン含有粉体 | |
CN113101406B (zh) | 一种淀粉组合物及其在制备止血材料中的应用 | |
JP2024115542A (ja) | オリゴ糖の吸湿性の改善 | |
JP7274813B2 (ja) | 糖質素材が非アミノ酸素材で被覆されている経口組成物 | |
JP4844901B2 (ja) | キトサン含有粉体 | |
JPH02124894A (ja) | フィチン酸安定化組成物 | |
Shao et al. | Effect of activated carbon or hydrogen peroxide decolorization on the structure and application properties of polysaccharides from Thesium chinense Turcz. | |
JP2009046436A (ja) | コーティング方法及び処理物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200827 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210305 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210427 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210517 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6887025 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |